These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 18598094)

  • 1. Haemoglobin A1c goal attainment in relation to dose in patients with diabetes mellitus taking metformin: a nested, case-control study.
    Penning-van Beest FJ; Wolffenbuttel BH; Herings RM
    Clin Drug Investig; 2008; 28(8):487-93. PubMed ID: 18598094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of time to treatment intensification on glycemic goal attainment among patients with type 2 diabetes failing metformin monotherapy.
    Rajpathak SN; Rajgopalan S; Engel SS
    J Diabetes Complications; 2014; 28(6):831-5. PubMed ID: 25104238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glycemic control in patients with type 2 diabetes mellitus switched from twice-daily immediate-release metformin to a once-daily extended-release formulation.
    Fujioka K; Pans M; Joyal S
    Clin Ther; 2003 Feb; 25(2):515-29. PubMed ID: 12749511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of non-persistent use of oral glucose-lowering drugs on HbA1c goal attainment.
    Penning-van Beest FJ; van der Bij S; Erkens JA; Kessabi S; Groot M; Herings RM
    Curr Med Res Opin; 2008 Sep; 24(9):2523-9. PubMed ID: 18812016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship of oral antihyperglycemic (sulfonylurea or metformin) medication adherence and hemoglobin A1c goal attainment for HMO patients enrolled in a diabetes disease management program.
    Lawrence DB; Ragucci KR; Long LB; Parris BS; Helfer LA
    J Manag Care Pharm; 2006; 12(6):466-71. PubMed ID: 16925454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycaemic control among patients with type 2 diabetes mellitus in seven European countries: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) study.
    Alvarez Guisasola F; Mavros P; Nocea G; Alemao E; Alexander CM; Yin D
    Diabetes Obes Metab; 2008 Jun; 10 Suppl 1():8-15. PubMed ID: 18435669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of initiation of therapy with once-daily combination of a thiazolidinedione and a biguanide at an early stage of type 2 diabetes.
    Bell DS; Ovalle F
    Diabetes Obes Metab; 2004 Sep; 6(5):363-6. PubMed ID: 15287929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of Add-on Treatment to Metformin Monotherapy for Patients with Type 2 Diabetes and Suboptimal Glycemic Control: A U.S. Database Study.
    Yu S; Schwab P; Bian B; Radican L; Tunceli K
    J Manag Care Spec Pharm; 2016 Mar; 22(3):272-80. PubMed ID: 27003557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial.
    Matthews DR; Paldánius PM; Proot P; Chiang Y; Stumvoll M; Del Prato S;
    Lancet; 2019 Oct; 394(10208):1519-1529. PubMed ID: 31542292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Twice-daily dapagliflozin co-administered with metformin in type 2 diabetes: a 16-week randomized, placebo-controlled clinical trial.
    Schumm-Draeger PM; Burgess L; Korányi L; Hruba V; Hamer-Maansson JE; de Bruin TW
    Diabetes Obes Metab; 2015 Jan; 17(1):42-51. PubMed ID: 25200570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of empagliflozin twice daily versus once daily in patients with type 2 diabetes inadequately controlled on metformin: a 16-week, randomized, placebo-controlled trial.
    Ross S; Thamer C; Cescutti J; Meinicke T; Woerle HJ; Broedl UC
    Diabetes Obes Metab; 2015 Jul; 17(7):699-702. PubMed ID: 25827441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamic population pharmacokinetic-pharmacodynamic modelling and simulation supports similar efficacy in glycosylated haemoglobin response with once or twice-daily dosing of canagliflozin.
    de Winter W; Dunne A; de Trixhe XW; Devineni D; Hsu CH; Pinheiro J; Polidori D
    Br J Clin Pharmacol; 2017 May; 83(5):1072-1081. PubMed ID: 28138980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of linagliptin 2.5 mg twice daily versus 5 mg once daily in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, placebo-controlled trial.
    Ross SA; Rafeiro E; Meinicke T; Toorawa R; Weber-Born S; Woerle HJ
    Curr Med Res Opin; 2012 Sep; 28(9):1465-74. PubMed ID: 22816729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial.
    Ludvik B; Giorgino F; Jódar E; Frias JP; Fernández Landó L; Brown K; Bray R; Rodríguez Á
    Lancet; 2021 Aug; 398(10300):583-598. PubMed ID: 34370970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical trial.
    Charbonnel B; Steinberg H; Eymard E; Xu L; Thakkar P; Prabhu V; Davies MJ; Engel SS
    Diabetologia; 2013 Jul; 56(7):1503-11. PubMed ID: 23604551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of AACE/ACE recommendations for initial dual antihyperglycemic therapy using the fixed-dose combination of sitagliptin and metformin versus metformin.
    Engel SS; Seck TL; Golm GT; Meehan AG; Kaufman KD; Goldstein BJ
    Endocr Pract; 2013; 19(5):751-7. PubMed ID: 23757615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Twice-daily and three-times-daily dosing of a repaglinide/metformin fixed-dose combination tablet provide similar glycaemic control.
    Raskin P; Lewin A; Reinhardt R; Lyness W;
    Diabetes Obes Metab; 2009 Oct; 11(10):947-52. PubMed ID: 19531054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Twice-daily dosing of a repaglinide/metformin fixed-dose combination tablet provides glycaemic control comparable to rosiglitazone/metformin tablet.
    Raskin P; Lewin A; Reinhardt R; Lyness W;
    Diabetes Obes Metab; 2009 Sep; 11(9):865-73. PubMed ID: 19476470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment escalation options for patients with type 2 diabetes after failure of exenatide twice daily or glimepiride added to metformin: results from the prospective European Exenatide (EUREXA) study.
    Schernthaner G; Rosas-Guzmán J; Dotta F; Guerci B; Simó R; Festa A; Kiljański J; Zhou M; Gallwitz B
    Diabetes Obes Metab; 2015 Jul; 17(7):689-98. PubMed ID: 25846577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Level of glycemic control among US type 2 diabetes mellitus patients on dual therapy of metformin and sodium-glucose cotransporter 2 inhibitor: a retrospective database study.
    Lautsch D; Iglay K; Yang L; Bansal N; Markan R; Kathe N; Rajpathak S
    Curr Med Res Opin; 2020 Oct; 36(10):1583-1589. PubMed ID: 32866052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.